Lexaria Bioscience
高管
查看带有其 8 名主要高管的组织结构图
Lexaria Bioscience 搜索最多的简介
- Richard Christopher, Chief Executive Officer
- Chris Bunka, Chairman of the Board
- Ted Mckechnie, Director
高管在Lexaria Bioscience变化
- Michael Shankman已作为Chief Financial Officer加入公司 (新闻发布的2024十月2号).
- Richard Christopher已作为Chief Executive Officer加入公司 (新闻发布的2024九月6号).
创建提醒
跟踪 Lexaria Bioscience 的高管变动
生物技术
Lexaria Bioscience 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
Lexaria Bioscience 的最新新闻稿
- Press Releases - Lexaria Bioscience
- Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
- Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
- Lexaria Updates Current GLP-1 Market
- Lexaria Appoints Michael Shankman as Chief Financial Officer
- Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
- Press Releases
- Lexaria Releases Strategic Letter from the Outgoing CEO
- View more press releases Close
通过电子邮件
